{Reference Type}: Systematic Review
{Title}: SAGES/AHPBA guidelines for the use of microwave and radiofrequency liver ablation for the surgical treatment of hepatocellular carcinoma or colorectal liver metastases less than 5 cm.
{Author}: Ceppa EP;Collings AT;Abdalla M;Onkendi E;Nelson DW;Ozair A;Miraflor E;Rahman F;Whiteside J;Shah MM;Ayloo S;Dirks R;Kumar SS;Ansari MT;Sucandy I;Ali K;Douglas S;Polanco PM;Vreeland TJ;Buell J;Abou-Setta AM;Awad Z;Kwon CH;Martinie JB;Sbrana F;Pryor A;Slater BJ;Richardson W;Jeyarajah R;Alseidi A;
{Journal}: Surg Endosc
{Volume}: 37
{Issue}: 12
{Year}: 2023 12 13
{Factor}: 3.453
{DOI}: 10.1007/s00464-023-10468-1
{Abstract}: Primary hepatocellular carcinoma (HCC) and colorectal liver metastases (CRLM) represent the liver's two most common malignant neoplasms. Liver-directed therapies such as ablation have become part of multidisciplinary therapies despite a paucity of data. Therefore, an expert panel was convened to develop evidence-based recommendations regarding the use of microwave ablation (MWA) and radiofrequency ablation (RFA) for HCC or CRLM less than 5 cm in diameter in patients ineligible for other therapies.<BR>A systematic review was conducted for six key questions (KQ) regarding MWA or RFA for solitary liver tumors in patients deemed poor candidates for first-line therapy. Subject experts used the GRADE methodology to formulate evidence-based recommendations and future research recommendations.<BR>The panel addressed six KQs pertaining to MWA vs. RFA outcomes and laparoscopic vs. percutaneous MWA. The available evidence was poor quality and individual studies included both HCC and CRLM. Therefore, the six KQs were condensed into two, recognizing that these were two disparate tumor groups and this grouping was somewhat arbitrary. With this significant limitation, the panel suggested that in appropriately selected patients, either MWA or RFA can be safe and feasible. However, this recommendation must be implemented cautiously when simultaneously considering patients with two disparate tumor biologies. The limited data suggested that laparoscopic MWA of anatomically more difficult tumors has a compensatory higher morbidity profile compared to percutaneous MWA, while achieving similar overall 1-year survival. Thus, either approach can be appropriate depending on patient-specific factors (very low certainty of evidence).<BR>Given the weak evidence, these guidelines provide modest guidance regarding liver ablative therapies for HCC and CRLM. Liver ablation is just one component of a multimodal approach and its use is currently limited to a highly selected population. The quality of the existing data is very low and therefore limits the strength of the guidelines.